Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?
Is RARE a good stock to buy? We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on r/ValueInvesting by u/Tallwhitedude123.
Ultragenyx Pharmaceutical Inc. (RARE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 2,500,000 | $37,575,000 | 1.19% | ||
| 2. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,339,293 | $35,159,574 | 1.11% | |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 1,339,814 | $20,137,404 | +45% | 0.15% |
| 4. | Birchview Capital Matthew Strobeck | 373,671 | $5,616,275 | 3.24% | |
| 5. | Walleye Capital Will England | 373,459 | $5,613,089 | +12% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.63 | 5,000 | $218,150.00 | 472,479 | 2019-09-11 | Filing | |
| $52.96 | 1,647 | $87,225.12 | 2,559,741 | 2017-08-28 | Filing | |
| $52.40 | 5,853 | $306,697.20 | 2,558,094 | 2017-08-28 | Filing | |
| $21.00 | 175,000 | $3,675,000.00 | 3,260,240 | 2014-01-31 | Filing | |
| $21.00 | 4,500 | $94,500.00 | 84,255 | 2014-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.27 | 7,066 | $107,897.82 | 89,229 | 2026-10-15 | Filing | |
| $13.57 | 1,283 | $17,410.31 | 67,863 | 2026-09-15 | Filing | |
| $13.99 | 161 | $2,252.39 | 69,146 | 2026-09-03 | Filing | |
| $24.92 | 1,900 | $47,348.00 | 92,562 | 2026-08-03 | Filing | |
| $24.92 | 4,696 | $117,024.32 | 96,295 | 2026-08-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,432,853 | $171,835,781 | 0% | |
| 2. | 8,419,105 | $126,539,148 | 0.01% | |
| 3. | 7,538,078 | $113,297,312 | 0% | |
| 4. | 4,299,168 | $64,616,495 | 0% | |
| 5. | 2,174,052 | $32,683,698 | 0% |
News See All
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) just added another commercial product to its portfolio.
Why Is Ultragenyx Pharmaceutical Stock (RARE) Down Today?
Ultragenyx Pharmaceutical stock fell over 46% on Thursday following a clinical trial update.
Ultragenyx (RARE) Jumped 7.5% on FDA Approval. Can a $2.7 Million Gene Therapy Become a Commercial Success?
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was up 7.5% in after-hours trading as of approximately 5:33 p.m.
Ultragenyx Pharmaceutical (RARE) Stock Jumps 9% on Accelerated FDA Approval
Ultragenyx Pharmaceutical stock rallied 8.99% on Thursday after the FDA granted Ultragenyx Pharmaceutical’s GENGLYCOS accelerated approval.
12 Best Buy-the-Dip Stocks to Invest In Now
In this article, we will take a look at some of the best buy-the-dip stocks that are currently offering attractive upside potential. On June 5, CNBC reported that U.S.
10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds
In this article, we will take a look at some of the best mid-cap healthcare stocks that are being highly favored by hedge funds.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2026 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2026 Earnings Call Transcript May 6, 2026 Operator: Good afternoon, and welcome to Ultragenyx First Quarter 2026 Financial Results Conference Call.
10 Best Biotech Stocks with Highest Upside Potential
In this article, we will take a look at some of the best biotech stocks that are currently offering attractive upside to investors. On April 16, reports from J.P.
10 Overlooked Growth Stocks to Buy Now
In this article, we will discuss the 10 Overlooked Growth Stocks to Buy Now. On April 14, Tom Lee, Fundstrat's Head of Research, joined CNBC's 'Power Lunch' to discuss his outlook on equities.
Hedge Fund Resource Center